Intel (NASDAQ: INTC) and Taiwan Semiconductor Manufacturing (NYSE: TSM) are holding discussions with the White House about building chip plants in the U.S.
Service Properties (SVC) came out with quarterly funds from operations (FFO) of $0.75 per share, missing the Zacks Consensus Estimate of $0.89 per share. This compares to FFO of $0.88 per share a year ago. These figures are adjusted for non-recurring items.
Activision Blizzard (NASDAQ: ATVI) reported a strong first quarter with revenue and earnings blowing past analysts' expectations. Most importantly, the game maker is poised to maintain strong performance through the rest of the year, despite the impact of the COVID-19 outbreak.
The Wall Street rally which commenced on Mar 24 has not yet shown any sign of retreat. Many economists and financial researchers have called this a "bear-market rally." What is remarkable here is that the rally is crossing one hurdle after another such as disappointing economic
EU antitrust regulators will decide by June 17 whether to clear Fiat Chrysler and Peugeot maker PSA's $50 billion merger, according to a European Commission filing on Monday.
(RTTNews) - German stocks edged up slightly on Monday even as the latest data indicated the coronavirus infection rate was rising again after loosening restrictions.
(RTTNews) - Volkswagen Group (VKW.L, VLKAF.PK, VOW.BE) Monday said the sales in the month of April continued to fall sharply due to Coronavirus crisis.
(RTTNews) - Asian stocks ended broadly higher on Monday as hopes of reopening of economies and signs of a slowing coronavirus death rate in some of the world's worst-hit countries helped investors shrug off a staggering jump in U.S. job losses.
(RTTNews) - The UK's Competition and Markets Authority or CMA Monday announced the launch of a merger inquiry into the deal with French food company Danone SA (DANOY.OB) and Harrogate Water Brands Limited, which owns British bottled water brand Harrogate Spring Water.
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Monday that the U.S. Food and Drug Administration has granted Enhertu (trastuzumab deruxtecan) Breakthrough Therapy Designation or BTD in the US.